Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HOD - .19 and moving up
The Dilemma
I am trying to decide to sit on cash to buy VJET in the secondary market (cannot get in on the IPO) on Thursday/Friday or invest it now in SGLB.
Not sure which is the best use for now.
I have a sizeable stake already in SGLB.
Money is in 401K so I am a long term investor.
Any thoughts would be great.
.165 - Wow!
MDuffy - Very nice post. I really like your reasoning used on SGLB.
Please keep these well thought out informative posts coming.
Stellar’s $12M raise sets stage for drug rollout
Dear Stellar Biotechnologies Supporter:
See below today’s story in Pacific Coast Business Times
Stellar’s $12M raise sets stage for drug rollout
By Stephen Nellis on October 11, 2013
Port Hueneme-based Stellar Biotechnologies has closed a $12 million round of financing and acquired a license for what could one day be its first drug.
Stellar gained notoriety in the research world by snatching up a facility inside the Port of Hueneme gates during a round of base closings in the late 1990s. It used that facility to sustainably cultivate giant keyhole limpets. The mollusks produce what is known as keyhole limpet hemocyanin, or KLH, a carrier protein for vaccines that previously had to be harvested from the wild.
Frank Oakes, Stellar’s CEO, said the company has been focused on moving up the value chain. In the past, it provided raw KLH material that other companies would then purify and sell to researchers for integration into therapies. Stellar has developed the ability purify its proteins in house. And in July, it acquired a license to patents covering a potential treatment for infections of Clostridium difficile, or C. diff, a common infection in hospitals. Read the full story…..
http://www.pacbiztimes.com/2013/10/11/stellars-12m-raise-sets-stage-for-drug-rollout/
Learn more about KLH and its vital importance to vaccines and immunology, visit www.KLHsite.com. Read more about Stellar at www.stellarbiotechnologies.com.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.
To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.
Contacts:
Frank Oakes
President and CEO
Phone +1 (805) 488-2800
investorrelations@stellarbiotech.com
Investor Relations:
MZ Group
Mark A. McPartland
Senior Vice President
Phone: +1 (646) 593-7140
markmcp@mzgroup.us
Web: www.mzgroup.us
Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.
Here we go again - 0.14 GLTA
I just sold some to move in on another investment and it moved the price. It takes very little at this low volume to move the price.
I will be back in when I see it moving up.
Gary - Thanks.
I am anxious to see where VoxelJet ends up on the first day. I bought Xone on the IPO day at about 27 and watched it go. Unfortunately I was not able to get in at the IPO price.
I really appreciate the info that you have made available on your website.
Regards,
Scott
How can the ADR be trading at $3 less than the stock in Sweden?
AMAVF = $119.50
ARCM.ST = $122.62
Yahoo uses the current exchange rate with converting the Kroner to dollars for ACRM.ST
Seems to be slowly moving up. Any ideas why? I have seen no news to encourage anyone to buy. They did claim at the investor's conference in early 2013 that they expected revenue in Q1 2014. I have seen nothing that shows this will really happen.
Does anyone know why Tengion TNGN was up 17% today? I cannot find any news.
I saw the article and someone added a comment that mentioned SGLB. I believe it was the first comment.
Dump already happened!
So far, today is a good day. Up 6% on very low volume.
Looks like today could be very good. Just hit 11 cents.
Wow - .098 - Ten cents soon!
I am here with you. Any idea on the pop?? I got in at 5 cents and am happy!
I believe the following Taiwanese Company is involved in 3D printing:
MICROJET (8197.TWO)-Taiwan OTC
Echo Automotive To Exhibit At 2013 Green Fleet Conference
EchoDrive to Greet Fleet Professionals Interested in Greening & Improving Efficiency
Scottsdale, AZ--(MARKETWIRE-September 12, 2013) - Echo Automotive, Inc. (OTCQB: ECAU) ("Echo Automotive", "Echo" or the "Company") a developer of technologies enabling the cost-effective aftermarket addition of fuel-efficient plug-in hybrid capability to new and existing vehicles, today announced that its industry award-winning EchoDrive? system will be exhibited October 1-2, 2013 in booth 600 at the 6th Annual Green Fleet Conference & Expo, the largest gathering of fleet professionals interested in greening and improving the efficiencies of their fleets. The event will be held at the Phoenix Convention Center in Phoenix, AZ.
"The Green Fleet Conference is an event that focuses on fleets with an environmental sustainability component. Attendees are interested in innovative technologies, like EchoDrive, that will help them achieve their green objectives while improving efficiency and reducing operating costs," explains Amy Dobrikova, Echo's Vice President of Sales and Business Development. "We look forward to being part of this event and to showing how EchoDrive can give these industry-leading fleets an easy-to-implement, easy-to-use, plug-in hybrid option that can be installed on vehicles they already own and use today without affecting the OEM powertrain. It's a revolutionary approach that allows Echo customers to increase fuel efficiency up to 50% while lowering operating expenses and reducing emissions."
The Green Fleet Conference will be held Oct 1-2, 2013 at the Phoenix Convention Center. The organizers expect more than 400 fleet professionals to participate in two intense and focused days of education and interaction geared exclusively toward improving fleet efficiency and sustainability.
About Echo Automotive, Inc. (OTCQB: ECAU)
Echo Automotive? is a technology company that specializes in delivering cost-effective electrification products and solutions that are purpose-built to maximize fleet transportation efficiency and provide optimal return on investment. The key to Echo's strategy is the bolt-on nature of its solutions, which reduce operating costs and increase range and efficiency without affecting original vehicle operations. Additionally, Echo offers technology licensing, and consulting in design, energy storage, propulsion, conversions, and vehicle engineering. For more information, please visit www.echoautomotive.com.
About the 6th Annual Green Fleet Conference & Expo
Presented by Automotive Fleet Magazine, the authority in fleet vehicle management for over 50 years, and its dedicated publication, Green Fleet Magazine, the 6th Annual Green Fleet Conference & Expo is the largest gathering of fleet professionals interested in greening and improving the efficiencies of their fleets. For more information, visit http://www.greenfleetconference.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new technologies and development stage companies. These forward-looking statements are made as of the date of this news release and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our current report on Form 8-K filed October 15, 2012, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
CONTACT:
David Waldman/Natalya Rudman
Crescendo Communications, LLC
Tel: 212-671-1020 x304
Email: ECAU@crescendo-ir.com
www.EchoAutomotive.com
Nice article
What else are they doing to raise revenue from today until 2015 when this mine will start producing?
Echo Automotive's EchoDrive(TM) Featured at GE Vehicle Innovation Center
SCOTTSDALE, AZ--(Marketwired - Sep 10, 2013) - Echo Automotive, Inc. (OTCQB: ECAU) ("Echo Automotive," "Echo" or the "Company") a developer of technologies enabling the cost-effective conversion of new and existing fleet vehicles into fuel-efficient hybrids and plug-in hybrids, today announced that its EchoDrive™ plug-in hybrid solution is now featured at the GE Vehicle Innovation Center. The EchoDrive demonstration vehicle will be on-site through November 26, 2013 allowing GE fleet experts, customers and guests to test-drive the industry award-winning hybrid conversion technology.
"EchoDrive is something that drivers need to experience personally to fully appreciate the system's robust capability, simply elegant design, and ease of use. It's not until someone gets behind the wheel that they realize just how seamless, quiet and effective bolt-on aftermarket hybrid technology can be," said Jason Plotke, President and Chairman of Echo. "We are delighted to have the opportunity to showcase EchoDrive at GE's Vehicle Innovation center, and are looking forward to having their in-house experts and customers put it to the test."
Echo Automotive is offering hands-on training workshops for GE representatives to demonstrate the full range of capabilities of the EchoDrive platform and to ensure Vehicle Innovation Center visitors have access to the EchoDrive information they need in addition to the expert care and guidance they trust and rely upon from their GE representatives.
About Echo Automotive, Inc. (OTCQB: ECAU)
Echo Automotive, Inc. develops and delivers technologies and products that enable cost-effective conversion of new and existing vehicles into fuel-efficient hybrids and plug-in hybrids. The key to Echo's strategy is the bolt-on nature of its solutions, which reduce operating costs and increase range and efficiency without affecting original vehicle operations. Additionally, Echo offers technology licensing, and consulting in design, energy storage, propulsion, conversions, and vehicle engineering. For more information, please visit www.echoautomotive.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, use of the proceeds from the financing transactions with United Fleet, increase in order fulfillment operations, growing demand for EchoDrive™ kits, development of technologies and products, and business strategy. These forward-looking statements are made as of the date of this news release and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K filed April 16, 2012, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
The big question is where are they planning to go with Bright Automotive's IP? Read last paragraph.
Excerpt from Recent 10-Q
Overview
We were organized under the laws of the State of Nevada on September 2, 2008 under the name Canterbury Resources, Inc.
On August 27, 2012 we effected a stock dividend of four shares of common stock of the Company for each share of common
stock issued and outstanding. Effective September 24, 2012, we amended our Articles of Incorporation to change our name
from “Canterbury Resources, Inc.” to “Echo Automotive, Inc.”
On October 11, 2012 we closed a voluntary exchange transaction (the “Exchange” or “Exchange Transaction”) with Echo
Automotive, LLC, an Arizona limited liability company (“Echo LLC”) and DBPJ Stock Holding, LLC, an Arizona limited
liability company and sole member of Echo (the “Echo LLC Member”) pursuant to an Exchange Agreement dated September
21, 2012 (the “Exchange Agreement”) by and among the Company, Echo LLC, and the Echo LLC Member. As a result of the
Exchange, the Echo LLC Member acquired 70% of our issued and outstanding common stock, Echo LLC became our sole
wholly-owned subsidiary, and we acquired the business and operations of Echo LLC.
Through Echo LLC, we are now a development stage company with several technologies and methods that allow commercial
fleet vehicles to significantly reduce their overall fuel expenses. Our business plan is based on providing the marketplace with a business proposition for reducing the use of fossil fuels by augmenting power trains within existing commercial fleet
vehicles with highly efficient electrical assist delivered through electric motors powered by our modular plug-in batteries to achieve rapid real-world operating results including a rapid return on the investment for such amended vehicles.
Bright Automotive, Inc. was established in 2008 as an offspring of the non-profit Rocky Mountain Institute to commercialize
and develop the IDEA plug-in hybrid electric fleet vehicle. Bright Automotive ceased operations in March 2012 after failing to
obtain a loan through the Advanced Technology Vehicles Manufacturing Loan Program. We successfully hired key members
of the Bright Automotive team and acquired certain facilities and intellectual property in a bid to accelerate EchoDrive TM’s
commercialization in spring of 2012. In the first quarter of 2013, Bright Automotive, Inc.’s assets, including all of its
intellectual properties and patents, were auctioned off and were purchased by Advanced Technical Asset Holdings, LLC (“ATAH”). On April 5, 2013, we acquired ATAH for 6,000,000 shares of our common stock as part of an exchange agreement with ATAH in which we received full ownership of the assets described above (“ATAH Exchange”). We plan to use the intellectual property and patents to develop additional electrification solutions for the marketplace.
Any idea what is driving the price here? I have seen no news.
Ian Cooper's Speed Retirement System
I just received a 16 page special report in my September Issue of NewsMax. It is a 100% pump on Arch Therapeutics.
Here is a quote, "If you can buy ARTH for around $2.00, make your move now".
Of course I bought some. I hope to ride this up and sell before the dump.
GLTA
ECHO AUTOMOTIVE PROVIDES BUSINESS UPDATE AND FILES SECOND QUARTER 2013 RESULTS
Reports Progress on Pilot Program and Expanded Service Network
Scottsdale, AZ and Anderson, IN - August 29, 2013 - Echo Automotive, Inc. (OTCQB: ECAU) ("Echo Automotive," "Echo" or the "Company"), a developer of technologies enabling the cost-effective conversion of new and existing fleet vehicles into fuel-efficient hybrids and plug-in hybrids, today announced that it has filed financial results for the three and six months ended June 30, 2013, with the U.S. Securities and Exchange Commission ("SEC"). The Company also reported continued progress on its EchoDrive? aftermarket hybrid conversion platform, including advanced discussions with major fleet operators regarding its pilot program to commence later this year. The Company remains on track to commence full-scale commercial production in 2014.
"The Company is making great progress on the development and services fronts, and is on track to launch the EchoDrive pilot program later this year," said Jason Plotke, President and Chairman, Echo Automotive. "We are in advanced discussions with a number of major fleet operators that have expressed significant interest in working with us because we offer a simply elegant solution and non-invasive technology that is easy to understand and even easier to use. We offer the lowest cost plug-in hybrid option on the market, and we can effectively demonstrate the value we can drive to the customer's bottom line. In addition, we have expanded our installation and service network, which now includes over 1,800 service locations and coverage in all 50 states."
"Upon completion of the pilot phase, we look forward to transitioning into full-scale commercialization of the technology in 2014. Initially, the EchoDrive platform will be configured for the Ford E-250 series, which is the industry leader in its category and a clear favorite of light-to-medium duty fleet operators as evidenced by nearly 600,000 registered E-series fleet vehicles," added Dan Kennedy, CEO, Echo Automotive. "Over time, additional configurations for other makes and models will be strategically added to the EchoDrive platform to ensure we serve the diverse and evolving needs of our target market."
Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit our website at: www.echoautomotive.com.
About Echo Automotive, Inc. (OTCQB: ECAU)
Echo Automotive? is a technology company that specializes in delivering cost-effective electrification solutions that are purpose-built to maximize fleet transportation efficiency and provide optimal return on investment. The company's initial offering, EchoDrive?, is a bolt-on aftermarket hybrid conversion platform that augments existing fleet vehicle capabilities while reducing operating costs and increasing range and efficiency without affecting existing vehicle operations. Additionally, Echo offers technology licensing, and consulting in design, energy storage, propulsion, conversions, and vehicle engineering. For more information, please visit www.echoautomotive.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new technologies and development stage companies. These forward-looking statements are made as of the date of this news release and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our current report on Form 10-K filed August 16, 2013, and our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
CONTACT:
David Waldman/Natalya Rudman
Crescendo Communications, LLC
Tel: 212-671-1020 x304
Email: ECAU@crescendo-ir.com
www.EchoAutomotive.com
Bought 50K at $0.17
GLTA
I just look him up on LinkedIn and his entire profile is there. Here is what I found:
Alan Yarborough
President and CEO at ExNovo
Location
Washington D.C. Metro Area
Industry
Defense & Space
Current
ExNovo,
Centre Analytics International, Inc.
You may contact me directly at alan@exnovoworldwide.com. 305.395.8615.
Previous
Executive Office of the President l The White House Office of National Drug Control Policy,
Merrill Lynch,
U.S. Army Security Coordination Detachment
Education
Columbia University - School of International and Public Affairs
Twitter
Websites Company Website
Gen-ed Foundation
Darfur Action Group of SC
Public Profile
www.linkedin.com/in/ayarborough
Contact Info
Summary
Principle and founding partner at ExNovo Solutions Inc. and Allotrope Sciences Corporation.
Founder and CEO, Centre Analytics International, Inc.
Specialties: Technology based R&D for the Department of Defense; Defense Policy Research; Strategic Communications Services; Medical Intelligence Services; National Security Community Transformation, DoD Manpower Outsourcing; Technology Consulting; Management Process Consulting; Specialized Training Programs.
Experience
President and C.O.O.
ExNovo
February 2011 – Present (2 years 7 months)Murrells Inlet, SC
Home | ExNovo. We Dare That Others May Live.
Founder and CEO
Centre Analytics International, Inc.
June 2001 – Present (12 years 3 months)
Consulting firm specializing in policy analysis, executive level advisory services, and intelligence support services to the USG and a select private client group. Centre Analytics also provides strategic level security and infrastructure development planning and consulting services.
Military Advisor Joint Task Force Six
Executive Office of the President l The White House Office of National Drug Control Policy
June 1998 – May 2001 (3 years)Philadelphia HIDTA
Direct detail assignments through ONDCP to: US Border Patrol and the US Marshal Service (Philadelphia HIDTA)
Financial Consultant
Merrill Lynch
April 1996 – May 1998 (2 years 2 months)
Provided planning-based financial advice and portfolio investment strategy advice to individuals and small businesses.
Counterintelligence
U.S. Army Security Coordination Detachment
October 1984 – February 1995 (10 years 5 months)
U.S. Army Security Coordination Detachment
Counterintelligence; finished off my Active Duty time in Northern VA.
527th MI Bn.
Worked Defensive Counterespionage in Europe during the height of the Cold War. 1988-1992
Skills & Expertise
Alan also knows about...
12Public Policy
11Intelligence Collection
11HUMINT
11Leadership
11Crisis Management
9National Intelligence
7Executive Management
7Security
6Intelligence Analysis
6Policy Analysis
6Government Contracting
6Training
5Operational Planning
5Homeland Security
5Strategic Communications
4Competitive Intelligence
4International Relations
4Organizational...
3Entrepreneurship
3Big Data
3Asymmetric Warfare
2R&D
2Tactics
1Reconnaissance and...
1Special Operations
1Security Operations
Education
Columbia University - School of International and Public Affairs
Seminar, Public Policy
2005 – 2005
Seminar - The Ambiguities of Freedom: Public Policy and American Youth
University of Cambridge
Seminar, International Relations
2005 – 2005
Seminar - Islam and Muslims in the Mind of America
London School of Economics and Political Science
Seminar, International Relations -
2004 – 2004
Seminar - A Clash of Ideologies: Al Qaeda, America and Academia; The Middle East and the West: Misunderstandings and Stereotypes
SUNY Albany
BS-Liberal Arts, Political Science and Psychology
1998 – 2001
University of Maryland University College
Psycholgy, Pol Sci
1988 – 1991
European Campus - Germany
Georgia Military College
General Studies and Criminal Justice
1985 – 1988
Georgia Military College - Fort Gordon, Augusta Georgia
Additional Info
Interests
Defense Policy,
Preventative Defense,
Intelligence Community Transformation,
Environmental Issues,
Leadership,
Public Service,
Philanthropy,
Business Intelligence,
Integrated Communications,
Public Relations,
Emerging Markets,
Globalization,
Developing Nations,
Infrastructure Development,
Government Process Efficiency,
Access to Health Care policy issues,
Human Rights,
Genocide,
Private Equity/Venture Capital opportunities,
Micro-Loans and Social Investing,
Forex Trading.
Personal Details
Advice for Contacting Alan
Contact us through email at gc@exnovoworldwide.com. Please include brief details of any joint project proposals. If you have an urgent request for services please include as much info as you can without compromising security. Practice good OPSEC please. You may contact me directly at alan@exnovoworldwide.com. 305.395.8615.
Organizations
Additional Organizations
High IQ for Humanity, GenEd Foundation, Darfur Action Group of SC, The Social Foundation, Habitat for Humanity
Al - I am happy to see that they went about the required financing smartly. Unlike SGLB (Sigma Labs) who sold off 25% of the company for about 1 cent per share when the stock price was over 10 cents.
Overall - I am very happy with this company and happy that I listened to Nick Hodge's teaser and then figured out who the company was without paying Nick anything.
Stellar Biotechnologies, Inc. Announces US $12,000,000 Private Placement
PORT HUENEME, CA--(Marketwired - Aug 22, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announces its intent to close a private placement of up to 11,428,572 units (the "Units") to raise gross proceeds of up to US$12,000,000 (the "Private Placement"). Each Unit will have a purchase price of US$1.05 and will consist of one common share in the capital of the Company and one-half of a transferable share purchase warrant (a "Warrant"). Each whole Warrant will entitle the holder to purchase one additional common share in the capital of the Company at a purchase price of US$1.35 for a period three years from the date of issuance of the Warrants.
The Private Placement will include a brokered portion to institutional and accredited investors (the "Brokered Offering") and a non-brokered portion (the "Non-brokered Offering"). The Company has retained Newport Coast Securities (the "Agent") as the exclusive placement agent to solicit, on a "best efforts" basis, subscription for the Brokered Offering. In consideration for its services, the Agent will receive a cash fee equal to 7% of the gross proceeds raised by the Agent in connection with the Brokered Offering (or 3.5% of the gross proceeds from excluded investors identified by the Company). The Agent will also receive agent warrants ("Agent Warrants") in an amount equal to 7% of the aggregate number of equity securities sold by the Agent. Each Agent Warrant will be exercisable for a period of three years from the date of issuance into one common share at a price equal to the issue price of the Brokered Offering. The Company will not pay a placement agent fee on the Non-brokered Offering.
The proceeds of the Private Placement will be used for product research, aquaculture and KLH production development, capital expenditures and working capital.
The securities issued will be subject to a hold period of four months and one day. Completion of the Private Placement is subject to the approval of the TSX Venture Exchange.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH operates as both a vital component in many active immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as an antigen for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and core KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of high-quality KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.
This press release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein. The securities have not been and will not be registered under the U.S. Securities Act, or any state securities laws and may not be offered or sold within the United States or to "U.S. persons" (as such term is defined in Regulation S promulgated under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Nether the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.
Stellar Biotechnologies, Inc. Announces US $12,000,000 Private Placement
PORT HUENEME, CA--(Marketwired - Aug 22, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announces its intent to close a private placement of up to 11,428,572 units (the "Units") to raise gross proceeds of up to US$12,000,000 (the "Private Placement"). Each Unit will have a purchase price of US$1.05 and will consist of one common share in the capital of the Company and one-half of a transferable share purchase warrant (a "Warrant"). Each whole Warrant will entitle the holder to purchase one additional common share in the capital of the Company at a purchase price of US$1.35 for a period three years from the date of issuance of the Warrants.
The Private Placement will include a brokered portion to institutional and accredited investors (the "Brokered Offering") and a non-brokered portion (the "Non-brokered Offering"). The Company has retained Newport Coast Securities (the "Agent") as the exclusive placement agent to solicit, on a "best efforts" basis, subscription for the Brokered Offering. In consideration for its services, the Agent will receive a cash fee equal to 7% of the gross proceeds raised by the Agent in connection with the Brokered Offering (or 3.5% of the gross proceeds from excluded investors identified by the Company). The Agent will also receive agent warrants ("Agent Warrants") in an amount equal to 7% of the aggregate number of equity securities sold by the Agent. Each Agent Warrant will be exercisable for a period of three years from the date of issuance into one common share at a price equal to the issue price of the Brokered Offering. The Company will not pay a placement agent fee on the Non-brokered Offering.
The proceeds of the Private Placement will be used for product research, aquaculture and KLH production development, capital expenditures and working capital.
The securities issued will be subject to a hold period of four months and one day. Completion of the Private Placement is subject to the approval of the TSX Venture Exchange.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH operates as both a vital component in many active immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as an antigen for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and core KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of high-quality KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.
This press release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein. The securities have not been and will not be registered under the U.S. Securities Act, or any state securities laws and may not be offered or sold within the United States or to "U.S. persons" (as such term is defined in Regulation S promulgated under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Nether the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.
Stellar Biotechnologies, Inc. Announces US $12,000,000 Private Placement
PORT HUENEME, CA--(Marketwired - Aug 22, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announces its intent to close a private placement of up to 11,428,572 units (the "Units") to raise gross proceeds of up to US$12,000,000 (the "Private Placement"). Each Unit will have a purchase price of US$1.05 and will consist of one common share in the capital of the Company and one-half of a transferable share purchase warrant (a "Warrant"). Each whole Warrant will entitle the holder to purchase one additional common share in the capital of the Company at a purchase price of US$1.35 for a period three years from the date of issuance of the Warrants.
The Private Placement will include a brokered portion to institutional and accredited investors (the "Brokered Offering") and a non-brokered portion (the "Non-brokered Offering"). The Company has retained Newport Coast Securities (the "Agent") as the exclusive placement agent to solicit, on a "best efforts" basis, subscription for the Brokered Offering. In consideration for its services, the Agent will receive a cash fee equal to 7% of the gross proceeds raised by the Agent in connection with the Brokered Offering (or 3.5% of the gross proceeds from excluded investors identified by the Company). The Agent will also receive agent warrants ("Agent Warrants") in an amount equal to 7% of the aggregate number of equity securities sold by the Agent. Each Agent Warrant will be exercisable for a period of three years from the date of issuance into one common share at a price equal to the issue price of the Brokered Offering. The Company will not pay a placement agent fee on the Non-brokered Offering.
The proceeds of the Private Placement will be used for product research, aquaculture and KLH production development, capital expenditures and working capital.
The securities issued will be subject to a hold period of four months and one day. Completion of the Private Placement is subject to the approval of the TSX Venture Exchange.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH operates as both a vital component in many active immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as an antigen for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and core KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of high-quality KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies. To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.
This press release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein. The securities have not been and will not be registered under the U.S. Securities Act, or any state securities laws and may not be offered or sold within the United States or to "U.S. persons" (as such term is defined in Regulation S promulgated under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Nether the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.
IIROC Trading Halt - KLHBY Canada NewsWire
— 4:14 PM ET 08/20/2013
VANCOUVER, Aug. 20, 2013 /CNW/ - The following issues have been halted by IIROC:
Company: STELLER BIOTECHNOLOGIES INC
TSX-Venture Symbol: KLH
Reason: At the Request of the Company Pending News
Halt Time (ET): 4:00 PM ET
The Investment Industry Regulatory Organization of Canada (IIROC) can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the company. Trading halts are issued based on the principle that all investors should have the same timely access to important company information. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC)
Up over 100% since June 27, 2013
It is amazing how few posts there are on this site since this stock has been up over 100% in 3 months. I am amazed there are so few who actually know about this stock and this site.
GLTA!
I drive by their office and warehouse building in Anderson, Indiana at least once a week. They now have a big sign on their section of the building where their offices are. They do not have a sign on their warehouse that is about 1/4 mile from their office. Looks like they have moved a few of their offices to the warehouse building. I looked through the windows of the warehouse and I saw one of the old Bright Automotive prototypes in the warehouse along with a lot of shelving that needed to be assembled.
I am told they are going to use the warehouse to build up their kits. According to the plan they laid out at the investor's meeting in early 2013, they are planning on 1st qtr 2014 sales. These sales will be in the form of kits that will be built and shipped from their warehouse in Anderson.
It appears they are still growing and I have seen no signs of them cutting back due to lack of funding. I do seriously question why they have not filed their 10K on time. Last time they did this they were waiting on some news to come out before they filed their report. Time will tell us what is up this time.
Great Video on Stellar. Not sure how old this is, but it is even better than Nick Hodge's teaser.
http://vimeo.com/57769111
Looks like the dump started today in a big way. How low can it go? I see it going to under a $1.00.
Any idea where this is going?
Current price is based upon a pump that did not really have the big dump yet. There has not been any real news of products being released soon.
I just wonder how low this can really go before they come out with some real news that might take the price back up.
I am a fan. I was in before the pump and profited from it. I am actually interested in getting back in once this all settles.
My big question is how low this is going to go before it finds a footing?
What is in 2 months?
Stellar Biotechnologies Issues President's Letter to Shareholders
Letter can be found at:
http://www.stellarbiotechnologies.com/_resources/letter.pdf
I notice you left the date off this article. Any particular reason why?